• No results found

University of Groningen Treatment outcomes in ANCA-associated vasculitis Hessels, Arno

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Treatment outcomes in ANCA-associated vasculitis Hessels, Arno"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Treatment outcomes in ANCA-associated vasculitis

Hessels, Arno

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Hessels, A. (2019). Treatment outcomes in ANCA-associated vasculitis: Determinants of efficacy and toxicity. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Treatment outcomes in

ANCA-associated vasculitis

Determinants of efficacy and toxicity

(3)

Arno Hessels

Treatment outcomes in ANCA-associated vasculitis: Determinants of efficacy and toxicity

Dissertation University of Groningen, The Netherlands Financial support by

the University of Groningen

University Medical Center Groningen

Graduate School for Drug Exploration (GUIDE) Vasculitis Stichting

are gratefully acknowledged.

ISBN:

978-94-6375-159-9 (printed version) 978-94-034-1493-5 (digital version) Cover design: Kristina Hristova Lay-out: Kristina Hristova

Printed by: Ridderprint B.V., Ridderkerk, the Netherlands

Further financial support for the printing of this thesis was kindly provided by Vifor Fresenius Medical Care Renal Pharma Ltd.

©A.C. Hessels 2018

All rights reserved. No part of this publication may be reproduced, copied, modified, stored in a retrieval system or transmitted without the prior permission in writing from the author.

(4)

Arno Christiaan Hessels

Treatment outcomes in

ANCA-associated vasculitis

Determinants of effi cacy and toxicity

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnifi cus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 20 maart 2019 om 16:15 uur

door

geboren op 28 juli 1992 te Zwolle

(5)

Promotor Prof. dr. C. A. Stegeman Copromotores Dr. A. Rutgers Dr. J. S. F. Sanders Beoordelingscommissie

Prof. dr. T. van Gelder Prof. dr. T. P. Links Prof. dr. S. P. Berger

(6)

Introduction: current challenges in the treatment of ANCA-associated vasculitis

Pharmacogenetics

Review: gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis

Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11β-hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor

Characterizing treatment outcomes

Geographic diff erences in clinical presentation and outcome of antineutrophil cytoplasmic antibody-associated vasculitis: role of antibody specifi city

Azathioprine hypersensitivity syndrome in a cohort of antineutrophil cytoplasmic antibody-associated vasculitis patients

Leg muscle strength is reduced and is associated with physical quality of life in antineutrophil cytoplasmic antibody-associated vasculitis

Summary and future perspectives Nederlandse samenvatting Dankwoord

About the author Chapter 1

Part 1

Chapter 2 Chapter 3 Chapter 4

Part 2

Chapter 5 Chapter 6 Chapter 7 Chapter 8 7 23 45 67 91 105 119 139

Contents

151 159 163

(7)

Referenties

GERELATEERDE DOCUMENTEN

In univariable linear regression, knee extension force, Baecke total score and neurological vasculitis activity at most recent disease episode (peripheral neuropathy (n=4) or

In Chapter 3, we fi nd that AAV patients carrying a TPMT variant do not have an increased risk of adverse eff ects during azathioprine maintenance therapy, at least if they

Voorbeelden van omgevingsfactoren zijn Staphylococcus aureus (deze bacterie wordt vaak in de neus van GPA patiënten gevonden) en de breedtegraad/blootstelling aan UV licht (verder

Ellis Herder, ontzettend bedankt voor je ondersteuning bij verschillende studies van dit proefschrift, maar in het bijzonder voor je harde werk bij de CURVE studie.. Jouw inzet is

During his PhD research, he streamlined a database for a large observa- tional cohort of ANCA-associated vasculitis patients, coordinated two prospective observational

Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis:

Geographic differences in manifestations and outcomes of ANCA-associated vasculitis can partly, though not fully, be explained by differences in ANCA specificity (chapter 5)

Within patients with functional HPA axis a dose of 7.5 mg is not likely to result in full suppression of the endogenous cortisol production and the fusing of (partially)